Compare Revvity Inc (RVTY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Wells Fargo & Co — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Wells Fargo & Co trades at $89.84 (market cap $265.99B). The key difference: Wells Fargo & Co is far larger — about 18.8× Revvity Inc's market cap, and Wells Fargo & Co pays the higher dividend (2.27%). Which is the better fit depends on your goals.
| RVTY | WFC | |
|---|---|---|
Market Cap | $14.18B | $265.99B |
Sector | Technology | Financials |
52-Week High | $130.94 | $96.40 |
52-Week Low | $82.26 | $73.42 |
Enterprise Value | $16.50B | — |
Dividend Yield | 0.22% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Wells Fargo (WFC) trades at $87.98, down 2.21% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 12.78, net income margin of 25.97%, and recent Q2 2026 earnings beat. CEO Charlie Scharf emphasized strategic initiatives at the 2026 healthcare conference (CNBC, 2026-09-09), while the bank expands its wealth management division (Bloomberg via Yahoo Finance, 2026-08-28).
Outlook is cautiously positive with a consensus price target of $97.64, though risks include volatile cash flows and regulatory scrutiny. Investment opportunity lies in sustained profitability improvements and ROTCE targets, but investors face headwinds from interest rate sensitivity and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
